Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is relatively common in populations exposed to malaria. This deficiency appears to provide some protection from this infection, but it can also cause hemolysis after administration of some antimalarial drugs, especially primaquine. The risk of drug-induced G6PD deficiency-related hemolysis depends on a number of factors including the G6PD variant, the drug and drug dosage schedule, patient status, and disease factors. Although a great deal is known about the molecular biology of G6PD, determining the potential for drug-induced hemolysis in the clinical setting is still challenging. This report discusses the potential strategies for assessing drug-induced G6PD deficiency-related hemolytic risk preclinically and in early clinical trials. Additionally, the issues important for conducting larger clinical trials in populations in which G6PD deficiency is prevalent are examined, with a particular focus on antimalarial drug development.
Beutler
Ernest
E
The Scripps Research Institute, La Jolla, California 92037, USA. beutler@scripps.edu
Duparc
Stephan
S
D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects*; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects*; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism*; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000201:enzymology*
D000634:Aminoquinolines; D000962:Antimalarials; C004331:pamaquine; D005954:Glucosephosphate Dehydrogenase